University of Oxford researchers launches phase 1 HIV vaccine trial (HIV-CORE 0052 trial) of a novel mosaic vaccine designed to induce T cells

The trial, part of the European Aids Vaccine Initiative, will involve 13 healthy HIV-negative adults aged 18-65 years old, not considered at high risk of infection, who will receive 1 dose of HIVconsvX vaccine followed by booster at 4 weeks.

Source:

PharmaTimes